Biolife solutions stock.

With Stirling, BioLife believes that total GAAP revenue in 2021 will exceed $100 million and the transaction is expected to be accretive on an adjusted Net Income per share basis (Non-GAAP) in ...

Biolife solutions stock. Things To Know About Biolife solutions stock.

BLFS BioLife Solutions, Inc. Earnings Date & History. Follow. $13.250.88 (+7.11%)4:00 PM 12/01/23. NASDAQ | $USD | Post-Market: $13.25 4:55 PM.BioLife Solutions stock quote and BLFS charts. Latest stock price today and the US's most active stock market forums.BioLife Solutions: Overcoming Challenges and Primed for Growth – An Optimistic Buy Recommendation Amid Revenue Surpassing Expectations and Anticipated DivestitureThe three major U.S. stock exchanges are the New York Stock Exchange (NYSE), the NASDAQ and the American Stock Exchange (AMEX). As of 2014, the NYSE is the largest and most prestigious of the three. The NASDAQ is a virtual stock exchange.10 Mar, 2023, 15:38 ET. BOTHELL, Wash., March 10, 2023 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS ), a leading supplier of class-defining bioproduction tools and services for the cell ...

Biolife Solutions stock has received a consensus rating of buy. The average rating score is and is based on 8 buy ratings, 0 hold ratings, and 0 sell ratings. What was the 52-week low for Biolife ...Aug 8, 2023 · BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of -27.78% and 10.07%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the ... Dec 1, 2023 · BioLife Solutions, Inc. (BLFS) Stock Price, Quote, News & Analysis BLFS BioLife Solutions, Inc. Stock Price & Overview 5.43K followers $10.95 -0.44 ( -3.86%) 4:00 PM 11/10/23 NASDAQ...

The stock lies in the middle of a very wide and strong rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 10.89% during the next 3 months and, with a 90% probability hold a price between $0.00000328 and $0.0002 at the end of this 3-month period.On December 15, 2022, BioLife Solutions, Inc. (NASDAQ:BLFS) stock closed at $18.77 per share. One-month return of BioLife Solutions, Inc. (NASDAQ:BLFS) was -11.46%, and its shares lost 48.63% of ...

The entity was merged with our wholly-owned subsidiary, BioLife Solutions, Inc., which was engaged as a developer and marketer of biopreservation media products for cells and tissues. Following the merger, we changed our name to BioLife Solutions, Inc. Principal Offices; Available InformationBioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.BOTHELL, Wash., Aug. 9, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies ("CGT") and the broader biopharma markets, today announced financial results for the three and six months …BioLife Solutions, Inc. (NASDAQ:BLFS – Get Free Report) shares fell 4.2% during trading on Monday . The company traded as low as $13.37 and last traded at $13.49. 76,840 shares changed hands ...

Complete BioLife Solutions Inc. stock information by Barron's. View real-time BLFS stock price and news, along with industry-best analysis.

Get in touch. BioLife Solutions Inc. 3303 Monte Villa Parkway, Suite 310, Bothell , WA 98021 USA. For assistance, please call us Monday through Friday (9:00 am to 5:00 pm PST) at:

Stock analysis for BioLife Solutions Inc (BLFS:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Get the latest BioLife Solutions Inc (BLFS) stock quote, charts, news, and other financial information to help you make more informed trading and investment decisions. See the company's financial performance, balance sheet, cash flow, and earnings per share for the fiscal Q2 2023 ended 6/30/23. Establishing ownership of stock depends on how the stock was purchased, according to the Securities and Exchange Commission. A brokerage firm may have purchased the stock or it may have been bought directly from the company.BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.BioLife Solutions Company Stats. As of December 2020. Industry Health Care Equipment & Services. ... BioLife Solutions (BLFS) Stock Key Data. Summary Additional Data …Complete BioLife Solutions Inc. stock information by Barron's. View real-time BLFS stock price and news, along with industry-best analysis.

Discover more Overcome the challenges of cell expansion and product preservation throughout CGT processing. Independent research demonstrates the medium and material used in sample cryopreservation impacts biologic viability. Formulation must be sterile, free from adventitious agents and qualified before use to remove susceptibility from batch-to …Stock. Governance. Analyst Coverage. Company. Company. Company. Press Releases. Events. Leadership. Board of Directors. Scientific Advisory Board. Quality Management System. ... Dr. Mathew was part of the founding team of BioLife Solutions, Inc., and is a co-developer of BioLife’s biopreservation media solutions. He is a co-inventor on ...Complete BioLife Sciences Inc. stock information by Barron's. View real-time BLFE stock price and news, along with industry-best analysis.In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on BioLife Solutions. The company’s shares closed last Thursday at $12.42, close to its 52-week low of $12.11.BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of -27.78% and 10.07%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the ...10 Mar, 2023, 15:38 ET. BOTHELL, Wash., March 10, 2023 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS ), a leading supplier of class-defining bioproduction tools and services for the cell ...

Broadridge Corporate Issuer Solutions, Inc. P.O. Box 1342 Brentwood, New York 11717 USA (877) 830 - 4936 [email protected]

BOTHELL, Wash., Jan. 17, 2023 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapy (CGT) and the broader biopharma markets, today announced the dates of its 2023 analyst day and upcoming …Hedge fund activity in BioLife Solutions, Inc. (NASDAQ:BLFS) Heading into the second quarter of 2020, a total of 9 of the hedge funds tracked by Insider Monkey were long this stock, a change of ...On average, Wall Street analysts predict. that Biolife Solutions's share price could reach $25.50 by Aug 10, 2024. The average Biolife Solutions stock price prediction forecasts a potential upside of 103.84% from the current BLFS share price of $12.51.View BioLife Solutions, Inc BLFS investment & stock information. Get the latest BioLife Solutions, Inc BLFS detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.Stock Price. $10.2. 2023-11-01. Market Capitalization. $457.1 M. 2023-11-01. Revenue. $161.8 M. FY, 2022. BioLife Solutions Summary. Company Summary. Overview. Bothell, WA-based BioLife Solutions, Inc. is a developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media ...Oct 16, 2023 · BioLife Solutions to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 16, 2023. BOTHELL, Wash. , March 9, 2023 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and... Wall Street Stock Market & Finance report, prediction for the future: You'll find the Biolife Solutions share forecasts, stock quote and buy / sell signals below. According to present data Biolife Solutions's BLFS shares and potentially its market environment have been in bearish cycle last 12 months (if exists). 7 dic 2020 ... Thomas Girschweiler sold 1600000 shares, an approximate value of $36 million, of the BioLife Solutions' stock to Casdin Capital LLC.We are revolutionizing regenerative medicine, biobanking and drug discovery by increasing the viability of biologics. BioLife Solutions is a class-defining cell and gene therapy bioproduction tools and services company. Our solutions give life science companies and clinical researchers significant improvement in shelf life and post-preservation ...Nov 27, 2023 · BioLife Solutions Stock Performance. BLFS stock opened at $14.08 on Monday. The business has a 50 day moving average of $12.13 and a 200-day moving average of $16.47. BioLife Solutions, Inc. has a 12-month low of $8.92 and a 12-month high of $26.89. The firm has a market cap of $619.96 million, a PE ratio of -5.94 and a beta of 1.57.

BioLife Solutions is a class-defining cell and gene therapy bioproduction tools and services company. Our solutions give life science companies and clinical researchers significant improvement in shelf life and post-preservation viability and function of biological materials. BioLife Solutions is one of Washington’s best places to work ...

Wall Street Stock Market & Finance report, prediction for the future: You'll find the Biolife Solutions share forecasts, stock quote and buy / sell signals below. According to present data Biolife Solutions's BLFS shares and potentially its market environment have been in bearish cycle last 12 months (if exists).

Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you.First, BioLife Solutions, Inc. stock is trading at 1.95x book value of equity, which may or may not represent a value proposition. However, it should also be noted the breakdown of its book value ...Nov 8, 2023 · Biolife Solutions stock has received a consensus rating of buy. The average rating score is and is based on 8 buy ratings, 0 hold ratings, and 0 sell ratings. What was the 52-week low for Biolife ... Broadridge Corporate Issuer Solutions, Inc. P.O. Box 1342 Brentwood, New York 11717 USA (877) 830 - 4936 [email protected] BioLife Solutions stock chart. #fintwits #money #wallstreet #stockmarket #stocks. 0 points. 1 comment. 1. 0 comments. share. save. 2. Posted by 2 years ago. I want to buy a trading bot, any recommendations here? 2. 3 comments. share. save. 1. Posted by 2 years ago. Adam Khoo FX trading. Hello! I got some courses a while back and have ...10 nov 2023 ... Byrnes covers the Healthcare sector, focusing on stocks such as Durect, Oncternal Therapeutics, and BioLife Solutions. According to TipRanks, ...The estimated net worth of Andrew G. Hinson is at least $207,858.00 as of June 15th, 2021. Mr. Hinson owns 17,675 shares of BioLife Solutions stock worth more than $207,858 as of November 3rd. This net worth approximation does not reflect any other investments that Mr. Hinson may own. Learn More about Andrew G. Hinson's net worth.See BioLife Solutions, Inc. (BLFS) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.

The estimated net worth of Troy Wichterman is at least $861,719.60 as of November 13th, 2023. Mr. Wichterman owns 67,480 shares of BioLife Solutions stock worth more than $861,720 as of November 18th. This net worth estimate does not reflect any other investments that Mr. Wichterman may own.According to the issued ratings of 5 analysts in the last year, the consensus rating for BioLife Solutions stock is Buy based on the current 5 buy ratings for BLFS. The average twelve-month price prediction for BioLife Solutions is $24.60 with a high price target of $28.00 and a low price target of $22.00. Learn more on BLFS's analyst rating ...7 dic 2020 ... Thomas Girschweiler sold 1600000 shares, an approximate value of $36 million, of the BioLife Solutions' stock to Casdin Capital LLC.SciSafe, a part of BioLife Solutions, is trusted by top biopharmas, CDMOs and CROs to store over 50 million samples at multiple cGMP-compliant facilities around the world. Applying substantial investments in facilities and 24/7 monitoring with unparalleled sample management expertise from +8°C to -196°C storage, we offer flexible, customer ...Instagram:https://instagram. anhuaser buschvanguard us growthvanguard russell 1000 growth etfifafx BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced ...Biolife Solutions stock has received a consensus rating of buy. The average rating score is and is based on 8 buy ratings, 0 hold ratings, and 0 sell ratings. What was the 52-week low for Biolife ... athene holdingsbest forex brokers for us citizens Historical daily share price chart and data for BioLife Solutions since 1992 adjusted for splits and dividends. The latest closing stock price for BioLife Solutions as of …BioLife Solutions Stock Up 7.1 %. Shares of NASDAQ BLFS opened at $13.25 on Monday. BioLife Solutions, Inc. has a one year low of $8.92 and a one year high of $26.89. The company has a debt-to ... inds etf Nov. 4, 2021, 04:05 PM. BOTHELL, Wash., Nov. 4, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (the "Company") (Nasdaq: BLFS), a leading supplier of class-defining bioproduction tools and services ...BOTHELL, Wash., July 7, 2020 / PRNewswire / -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced the closing of its public offering of 5,951,250 shares of common stock at the public offering price ...